A range of studies have targeted the ErbB/neuregulin axis as a therapeutic strategy for ALS (Liu et al., 2018; Modol-Caballero et al., 2020a, b; Tavassoly et al., 2020). This evidence concerns the gene EGFR and amyotrophic lateral sclerosis.